Decreased serum club cell secretory protein in asthma and chronic obstructive pulmonary disease overlap: a pilot study

Jee Youn Oh, Young Seok Lee, Kyung-Hoon Min, Gyu Young Hur, Sung Yong Lee, Kyung Ho Kang, Chin Kook Rhee, Seoung Ju Park, Jae Jeong Shim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Improvement in the diagnosis of asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO), and identification of biomarkers for phenotype recognition will encourage good patient care by providing optimal therapy. We investigated club cell secretory protein (CC-16), a protective and anti-inflammatory mediator, as a new candidate biomarker for diagnosing ACO. Patients and methods: We performed a multicenter cohort study. A total of 107 patients were divided into three groups - asthma, COPD, and ACO - according to the Spanish guidelines algorithm, and enrolled into the study. Serum CC-16 levels were measured using commercial ELISA kits. Results: Serum CC-16 levels were the lowest in patients with ACO. Low serum CC-16 levels were a significant marker for the ACO even after adjustment for age, sex, and smoking intensity. Serum CC-16 levels were positively correlated with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25%-75% of FVC, FEV1/FVC, vital capacity, and diffusing capacity of the lung for carbon monoxide, and were negatively correlated with smoking amount (pack-years), bronchodilator response, fractional residual capacity, residual volume, and number of exacerbations per year. FEV1 and serum CC-16 levels were significantly lower in patients with frequent exacerbations. Conclusion: Serum CC-16 has the potential to be a biomarker for ACO diagnosis and also treat frequent exacerbations in patients with chronic inflammatory airway diseases.

Original languageEnglish
Pages (from-to)3411-3417
Number of pages7
JournalInternational journal of chronic obstructive pulmonary disease
Volume13
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Chronic Obstructive Pulmonary Disease
Asthma
Vital Capacity
Forced Expiratory Volume
Serum
Proteins
Biomarkers
Smoking
Lung Volume Measurements
Residual Volume
Bronchodilator Agents
Carbon Monoxide
Multicenter Studies
Patient Care
Cohort Studies
Anti-Inflammatory Agents
Enzyme-Linked Immunosorbent Assay
Guidelines
Phenotype

Keywords

  • ACO
  • asthma
  • club cell secretory protein-16
  • COPD
  • exacerbation
  • smoking

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Decreased serum club cell secretory protein in asthma and chronic obstructive pulmonary disease overlap : a pilot study. / Oh, Jee Youn; Lee, Young Seok; Min, Kyung-Hoon; Hur, Gyu Young; Lee, Sung Yong; Kang, Kyung Ho; Rhee, Chin Kook; Park, Seoung Ju; Shim, Jae Jeong.

In: International journal of chronic obstructive pulmonary disease, Vol. 13, 01.01.2018, p. 3411-3417.

Research output: Contribution to journalArticle

@article{6405dfae095341e08dc715e5e79fde8d,
title = "Decreased serum club cell secretory protein in asthma and chronic obstructive pulmonary disease overlap: a pilot study",
abstract = "Purpose: Improvement in the diagnosis of asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO), and identification of biomarkers for phenotype recognition will encourage good patient care by providing optimal therapy. We investigated club cell secretory protein (CC-16), a protective and anti-inflammatory mediator, as a new candidate biomarker for diagnosing ACO. Patients and methods: We performed a multicenter cohort study. A total of 107 patients were divided into three groups - asthma, COPD, and ACO - according to the Spanish guidelines algorithm, and enrolled into the study. Serum CC-16 levels were measured using commercial ELISA kits. Results: Serum CC-16 levels were the lowest in patients with ACO. Low serum CC-16 levels were a significant marker for the ACO even after adjustment for age, sex, and smoking intensity. Serum CC-16 levels were positively correlated with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25{\%}-75{\%} of FVC, FEV1/FVC, vital capacity, and diffusing capacity of the lung for carbon monoxide, and were negatively correlated with smoking amount (pack-years), bronchodilator response, fractional residual capacity, residual volume, and number of exacerbations per year. FEV1 and serum CC-16 levels were significantly lower in patients with frequent exacerbations. Conclusion: Serum CC-16 has the potential to be a biomarker for ACO diagnosis and also treat frequent exacerbations in patients with chronic inflammatory airway diseases.",
keywords = "ACO, asthma, club cell secretory protein-16, COPD, exacerbation, smoking",
author = "Oh, {Jee Youn} and Lee, {Young Seok} and Kyung-Hoon Min and Hur, {Gyu Young} and Lee, {Sung Yong} and Kang, {Kyung Ho} and Rhee, {Chin Kook} and Park, {Seoung Ju} and Shim, {Jae Jeong}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/COPD.S174545",
language = "English",
volume = "13",
pages = "3411--3417",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Decreased serum club cell secretory protein in asthma and chronic obstructive pulmonary disease overlap

T2 - a pilot study

AU - Oh, Jee Youn

AU - Lee, Young Seok

AU - Min, Kyung-Hoon

AU - Hur, Gyu Young

AU - Lee, Sung Yong

AU - Kang, Kyung Ho

AU - Rhee, Chin Kook

AU - Park, Seoung Ju

AU - Shim, Jae Jeong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Improvement in the diagnosis of asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO), and identification of biomarkers for phenotype recognition will encourage good patient care by providing optimal therapy. We investigated club cell secretory protein (CC-16), a protective and anti-inflammatory mediator, as a new candidate biomarker for diagnosing ACO. Patients and methods: We performed a multicenter cohort study. A total of 107 patients were divided into three groups - asthma, COPD, and ACO - according to the Spanish guidelines algorithm, and enrolled into the study. Serum CC-16 levels were measured using commercial ELISA kits. Results: Serum CC-16 levels were the lowest in patients with ACO. Low serum CC-16 levels were a significant marker for the ACO even after adjustment for age, sex, and smoking intensity. Serum CC-16 levels were positively correlated with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25%-75% of FVC, FEV1/FVC, vital capacity, and diffusing capacity of the lung for carbon monoxide, and were negatively correlated with smoking amount (pack-years), bronchodilator response, fractional residual capacity, residual volume, and number of exacerbations per year. FEV1 and serum CC-16 levels were significantly lower in patients with frequent exacerbations. Conclusion: Serum CC-16 has the potential to be a biomarker for ACO diagnosis and also treat frequent exacerbations in patients with chronic inflammatory airway diseases.

AB - Purpose: Improvement in the diagnosis of asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO), and identification of biomarkers for phenotype recognition will encourage good patient care by providing optimal therapy. We investigated club cell secretory protein (CC-16), a protective and anti-inflammatory mediator, as a new candidate biomarker for diagnosing ACO. Patients and methods: We performed a multicenter cohort study. A total of 107 patients were divided into three groups - asthma, COPD, and ACO - according to the Spanish guidelines algorithm, and enrolled into the study. Serum CC-16 levels were measured using commercial ELISA kits. Results: Serum CC-16 levels were the lowest in patients with ACO. Low serum CC-16 levels were a significant marker for the ACO even after adjustment for age, sex, and smoking intensity. Serum CC-16 levels were positively correlated with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25%-75% of FVC, FEV1/FVC, vital capacity, and diffusing capacity of the lung for carbon monoxide, and were negatively correlated with smoking amount (pack-years), bronchodilator response, fractional residual capacity, residual volume, and number of exacerbations per year. FEV1 and serum CC-16 levels were significantly lower in patients with frequent exacerbations. Conclusion: Serum CC-16 has the potential to be a biomarker for ACO diagnosis and also treat frequent exacerbations in patients with chronic inflammatory airway diseases.

KW - ACO

KW - asthma

KW - club cell secretory protein-16

KW - COPD

KW - exacerbation

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=85056550868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056550868&partnerID=8YFLogxK

U2 - 10.2147/COPD.S174545

DO - 10.2147/COPD.S174545

M3 - Article

C2 - 30425470

AN - SCOPUS:85056550868

VL - 13

SP - 3411

EP - 3417

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -